Charles River Laboratories is diving headfirst into gene therapy with another acquisition, this time paying $292.5 million upfront for Maryland-based Vigene Biosciences.
Image: https://www.bizjournals.com
{iframe}https://www.bizjournals.com/washington/news/2021/05/20/charles-river-labs-acquires-vigene-biosciences.html{/iframe}